查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1386507

病毒載體製造市場報告：2030 年趨勢、預測與競爭分析

Viral Vector Manufacturing Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

病毒載體製造趨勢與預測

預計到 2030 年，全球病毒載體製造市場將達到 30 億美元，2024 年至 2030 年年複合成長率為 18.7%。該市場的主要促進因素是對基於病毒載體的治療的需求不斷增加、對病毒載體製造的投資增加以及病毒載體製造的技術進步。全球病毒載體製造市場的未來前景廣闊，製藥、生物製藥和研究機構市場充滿機會。

病毒載體製造市場洞察

Lucintel 預測，由於對治療癌症、罕見疾病和遺傳性疾病等多種疾病的細胞和基因療法的需求不斷增加，細胞和基因療法將在預測期內實現最高成長。

在這個市場中，製藥和生物製藥公司是最大的細分市場，因為它們開發和商業化基於病毒載體的治療方法，治療多種疾病，包括癌症、罕見疾病和感染疾病。這似乎將繼續成為市場的焦點。案件。

由於該地區製藥和生物技術行業對基於病毒載體的療法的需求不斷增加，預計北美在預測期內將出現最高成長。

本報告回答了 11 個關鍵問題：

  • Q.1. 細分市場中最有前途和高成長的機會是什麼？
  • Q.2.哪個細分市場將以更快的速度成長？為什麼？
  • Q.3.您認為哪些地區未來會出現更快的成長？為什麼？
  • Q.4. 影響市場動態的主要因素有哪些？市場的主要挑戰和商業風險是什麼？
  • Q.5. 這個市場的商業風險和競爭威脅是什麼？
  • Q.6.這個市場有哪些新趨勢？為什麼？
  • Q.7.市場客戶需求有何改變？
  • Q.8. 該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10. 該市場上的競爭產品有哪些？由於材料或產品替代而導致市場佔有率下降的威脅有多大？
  • Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球病毒載體製造市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球病毒載體製造市場趨勢（2018-2023）與預測（2024-2030）
  • 按類型分類的全球病毒載體製造市場
    • 腺病毒
    • 逆轉錄病毒
    • 腺結合病毒
    • 慢病毒
    • 質粒DNA
    • 其他
  • 按工作流程分類的全球病毒載體製造市場
    • 上游製造
    • 下游製造
  • 全球病毒載體製造市場（按應用）
    • 細胞和基因治療
    • 疫苗學
    • 研究及其他
  • 按最終用途分類的全球病毒載體製造市場
    • 藥品和生物製藥
    • 研究機構
    • 其他

第4章 2018-2030年分地區市場趨勢及預測分析

  • 全球病毒載體製造市場（按地區）
  • 北美洲病毒載體製造市場
  • 歐洲病毒載體製造市場
  • 亞太病毒載體製造市場
  • 其他區域病毒載體製造市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 按類型分類的全球病毒載體製造市場成長機會
    • 按工作流程分類的全球病毒載體製造市場成長機會
    • 全球病毒載體製造市場成長機會（按應用）
    • 全球病毒載體製造市場成長機會（依最終用途）
    • 按地區分類的全球病毒載體製造市場成長機會
  • 全球病毒載體製造市場的新興趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球病毒載體製造市場的產能
    • 全球病毒載體製造市場的合併、收購和合資企業
    • 認證和許可

第7章 主要企業概況

  • Merck
  • Lonza
  • FUJIFILM Diosynth Biotechnologies
  • Thermo Fisher Scientific
  • Cobra Biologics
  • Catalent
  • Wuxi Biologics
  • Takara Bio
  • Waisman Biomanufacturing
  • Genezen laboratories
簡介目錄

Viral Vector Manufacturing Trends and Forecast

The future of the global viral vector manufacturing market looks promising with opportunities in the pharmaceutical & biopharmaceutical and research institutes markets. The global viral vector manufacturing market is expected to reach an estimated $3.0 billion by 2030 with a CAGR of 18.7% from 2024 to 2030. The major drivers for this market are increasing demand for viral vector-based therapies, growing investment in viral vector manufacturing, and technological advancements in viral vector manufacturing.

A more than 150-page report is developed to help in your business decisions.

Viral Vector Manufacturing by Segment

The study includes a forecast for the global viral vector manufacturing by type, workflow, application, end use, and region.

Viral Vector Manufacturing Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Adenovirus
  • Retrovirus
  • Adeno-Associated Virus
  • Lentivirus
  • Plasmid DNA
  • Others

Viral Vector Manufacturing Market by Workflow [Shipment Analysis by Value from 2018 to 2030]:

  • Upstream Manufacturing
  • Downstream Manufacturing

Viral Vector Manufacturing Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Cell & Gene Therapy
  • Vaccinology
  • Research & Other Applications

Viral Vector Manufacturing Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Pharmaceutical & Biopharmaceutical
  • Research Institutes
  • Others

Viral Vector Manufacturing Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Viral Vector Manufacturing Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies viral vector manufacturing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the viral vector manufacturing companies profiled in this report include-

  • Merck
  • Lonza
  • Fujifilm Diosynth Biotechnologies
  • Thermo Fisher Scientific
  • Cobra Biologics
  • Catalent
  • Wuxi Biologics
  • Takara Bio
  • Waisman Biomanufacturing
  • Genezen Laboratories

Viral Vector Manufacturing Market Insights

Lucintel forecasts that cell and gene therapy is expected to witness highest growth over the forecast period due to growing demand for cell and gene therapies for the treatment of a wide range of diseases, including cancer, rare diseases, and genetic disorders.

Within this market, pharmaceutical and biopharmaceutical will remain the largest segment due to the fact that these pharmaceutical and biopharmaceutical companies companies are developing and commercializing viral vector-based therapies for a wide range of diseases, including cancer, rare diseases, and infectious diseases.

North America is expected to witness highest growth over the forecast period due to increasing demand for viral vector-based therapies from the pharmaceutical and biotechnology industries in the region.

Features of the Global Viral Vector Manufacturing Market

Market Size Estimates: Viral vector manufacturing market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Viral vector manufacturing market size by various segments, such as by type, workflow, application, end use, and region in terms of value ($B).

Regional Analysis: Viral vector manufacturing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, workflows, applications, end uses, and regions for the viral vector manufacturing market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the viral vector manufacturing market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the viral vector manufacturing market size?

Answer: The global viral vector manufacturing market is expected to reach an estimated $3.0 billion by 2030.

Q.2 What is the growth forecast for viral vector manufacturing market?

Answer: The global viral vector manufacturing market is expected to grow with a CAGR of 18.7% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the viral vector manufacturing market?

Answer: The major drivers for this market are increasing demand for viral vector-based therapies, growing investment in viral vector manufacturing and technological advancements in viral vector manufacturing.

Q4. What are the major segments for viral vector manufacturing market?

Answer: The future of the viral vector manufacturing market looks promising with opportunities in the pharmaceutical & biopharmaceutical and research institutes markets.

Q5. Who are the key viral vector manufacturing market companies?

Answer: Some of the key viral vector manufacturing companies are as follows:

  • Merck
  • Lonza
  • Fujifilm Diosynth Biotechnologies
  • Thermo Fisher Scientific
  • Cobra Biologics
  • Catalent
  • Wuxi Biologics
  • Takara Bio
  • Waisman Biomanufacturing
  • Genezen Laboratories

Q6. Which viral vector manufacturing market segment will be the largest in future?

Answer: Lucintel forecasts that cell and gene therapy is expected to witness highest growth over the forecast period due to growing demand for cell and gene therapies for the treatment of a wide range of diseases, including cancer, rare diseases, and genetic disorders.

Q7. In viral vector manufacturing market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to increasing demand for viral vector-based therapies from the pharmaceutical and biotechnology industries in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the viral vector manufacturing market by type (adenovirus, retrovirus, adeno-associated virus, lentivirus, plasmid DNA, and others), workflow (upstream manufacturing and downstream manufacturing), application (cell & gene therapy, vaccinology, and research & other applications), end use (pharmaceutical & biopharmaceutical, research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Viral Vector Manufacturing Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Viral Vector Manufacturing Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Viral Vector Manufacturing Market by Type
    • 3.3.1: Adenovirus
    • 3.3.2: Retrovirus
    • 3.3.3: Adeno-Associated Virus
    • 3.3.4: Lentivirus
    • 3.3.5: Plasmid DNA
    • 3.3.6: Others
  • 3.4: Global Viral Vector Manufacturing Market by Workflow
    • 3.4.1: Upstream Manufacturing
    • 3.4.2: Downstream Manufacturing
  • 3.5: Global Viral Vector Manufacturing Market by Application
    • 3.5.1: Cell & Gene Therapy
    • 3.5.2: Vaccinology
    • 3.5.3: Research & Other Applications
  • 3.6: Global Viral Vector Manufacturing Market by End Use
    • 3.6.1: Pharmaceutical & Biopharmaceutical
    • 3.6.2: Research Institutes
    • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Viral Vector Manufacturing Market by Region
  • 4.2: North American Viral Vector Manufacturing Market
    • 4.2.2: North American Viral Vector Manufacturing Market by End Use: Pharmaceutical & Biopharmaceutical, Research Institutes, and Others
  • 4.3: European Viral Vector Manufacturing Market
    • 4.3.1: European Viral Vector Manufacturing Market by Application: Cell & Gene Therapy, Vaccinology, and Research & Other Applications
    • 4.3.2: European Viral Vector Manufacturing Market by End Use: Pharmaceutical & Biopharmaceutical, Research Institutes, and Others
  • 4.4: APAC Viral Vector Manufacturing Market
    • 4.4.1: APAC Viral Vector Manufacturing Market by Application: Cell & Gene Therapy, Vaccinology, and Research & Other Applications
    • 4.4.2: APAC Viral Vector Manufacturing Market by End Use: Pharmaceutical & Biopharmaceutical, Research Institutes, and Others
  • 4.5: ROW Viral Vector Manufacturing Market
    • 4.5.1: ROW Viral Vector Manufacturing Market by Application: Cell & Gene Therapy, Vaccinology, and Research & Other Applications
    • 4.5.2: ROW Viral Vector Manufacturing Market by End Use: Pharmaceutical & Biopharmaceutical, Research Institutes, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Viral Vector Manufacturing Market by Type
    • 6.1.2: Growth Opportunities for the Global Viral Vector Manufacturing Market by Workflow
    • 6.1.3: Growth Opportunities for the Global Viral Vector Manufacturing Market by Application
    • 6.1.4: Growth Opportunities for the Global Viral Vector Manufacturing Market by End Use
    • 6.1.5: Growth Opportunities for the Global Viral Vector Manufacturing Market by Region
  • 6.2: Emerging Trends in the Global Viral Vector Manufacturing Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Viral Vector Manufacturing Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Viral Vector Manufacturing Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Merck
  • 7.2: Lonza
  • 7.3: FUJIFILM Diosynth Biotechnologies
  • 7.4: Thermo Fisher Scientific
  • 7.5: Cobra Biologics
  • 7.6: Catalent
  • 7.7: Wuxi Biologics
  • 7.8: Takara Bio
  • 7.9: Waisman Biomanufacturing
  • 7.10: Genezen laboratories